Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Preferred Stock Liabilities (2020 - 2021)

Candel Therapeutics' Preferred Stock Liabilities history spans 2 years, with the latest figure at $22.5 million for Q2 2021.

  • On a quarterly basis, Preferred Stock Liabilities changed 0.0% to $22.5 million in Q2 2021 year-over-year; TTM through Jun 2021 was $22.5 million, a 0.0% change, with the full-year FY2020 number at $22.5 million, changed N/A from a year prior.
  • Preferred Stock Liabilities hit $22.5 million in Q2 2021 for Candel Therapeutics, down from $26.6 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for CADL hit a ceiling of $26.6 million in Q3 2020 and a floor of $22.5 million in Q2 2020.